Idience Overview
- Founded
- 2019
- Status
- Private
- Latest Deal Type
- Series B
- Latest Deal Amount
- $33.9M
- Investors
- 5
Idience General Information
Description
Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells, helping cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 2, Baumoe-ro 27-gil
- Seocho-gu
- Seoul, 06752
- South Korea
+82 00-000-0000
Idience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series B) | 01-Oct-2020 | $33.9M | 000.00 | Completed | Clinical Trials - Phase 1 |
Idience Executive Team (5)
Idience Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Kiwoom Securities Company | Corporation | Minority | 000 0000 | 000000 0 | |
| Mirae Asset Capital | Other | Minority | 000 0000 | 000000 0 | |
| Seoul Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| TS Investment | Other | Minority | 000 0000 | 000000 0 | |
| Yuanta Investment | Venture Capital | Minority | 000 0000 | 000000 0 |